Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votesGovInfo API
Floor speeches, reports, bill textFederal Election Commission (FEC)
Campaign financeVoteView (UCLA)
Ideology scores (DW-NOMINATE)GovTrack.us
Misconduct data (CC0)U.S. Census Bureau
District demographics
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

Press ReleaseNeutral2024-06-13

GOP Congressman Who Used Psychedelics For Mental Health Slams FDA Panel’s MDMA Rejection (Op-Ed)

Morgan Luttrell
Morgan Luttrell
RTX-8 · Representative
Share:
Healthcare

Context

This press release from Representative Morgan Luttrell (R-TX) was published on Wed Jun 12 and titled "GOP Congressman Who Used Psychedelics For Mental Health Slams FDA Panel’s MDMA Rejection (Op-Ed)". It focuses on healthcare.

Full Text

GOP Congressman Who Used Psychedelics For Mental Health Slams FDA Panel’s MDMA Rejection (Op-Ed) GOP Congressman Who Used Psychedelics For Mental Health Slams FDA Panel’s MDMA Rejection (Op-Ed) In recent years, a quiet revolution has been unfolding within the realm of treatment for combat-related injuries: psychedelic therapies. Substances like MDMA, psilocybin and ibogaine are now at the forefront of cutting-edge research for their potential to alleviate severe conditions, particularly post-traumatic stress (PTS) and post-traumatic stress disorder (PTSD). Cally.Barry@ma… Thu, 06/13/2024 - 11:08 June 13, 2024
View original source →